Euroapi S.A. develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and intermediates for human and veterinary medicines and cosmetics. The company operates through two main business segments: API Solutions, which provides a portfolio of proprietary APIs including complex chemical synthesis molecules, biochemistry molecules derived from fermentation, and highly potent molecules; and CDMO Services, which offers contract development and manufacturing for innovative medicines, peptides, and oligonucleotides. Key product categories include prostaglandins, corticoids, hormones, anti-infectives, opiates, controlled substances, and Vitamin B12. Euroapi serves originator and generic pharmaceutical companies globally. The group operates five manufacturing sites and development centers in Europe, located in France, Germany, Hungary, and Italy. It was carved out from the Sanofi group, with the process completed in 2021, and listed on Euronext Paris in 2022. Notable acquisitions include BianoGMP in 2023 to strengthen capabilities in the oligonucleotide market.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - Specialty & Generic Homepage euroapi.com/en
Sector Healthcare IR page euroapi.com/en/investors
Tags
active pharmaceutical ingredients, cdmo, oligonucleotides, peptides, highly potent apis, complex chemical synthesis, fermentation, controlled substances, veterinary health, human health, cosmetics, particle engineering, BianoGMP, API Solutions, CDMO Services
Press page euroapi.com/en/press-releases

Metrics

Valuation  
Market cap € 1.389B
Market cap (USD) $ 1.535B
P/E -4.28
PEG —
P/BV 2.08
P/S 1.75
P/OCF 10.81
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE -23.8%
ROI -30.6%
ROIC -14.2%
Profit margin -24.9%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score -80.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 848.2M 911.9M 1.013B 976.6M 892.8M
Net profit -211.2M -130.6M -189.7M -15M -8.1M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price — — — 14.64 —
P/OCF — — — 30.61 —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (EUR) — 239M 264M 216M 161M 115M
↳ YoY growth +10.6% -18.1% -25.4% -28.8%
Borrowings, current (EUR) — 1.4M 100M 205M 50.6M 45.5M
Lease liabilities (EUR) — 22.7M 20.7M 20.1M 18.5M 19.9M
Cash and deposits (EUR) 0.00 10.3M 74.5M 34.5M 73M 114M
Intangible assets (EUR) — 26.8M 28.7M 34.2M 38.1M 26.7M
Right-of-use assets (EUR) — 45.6M 42.2M 37.2M 38M 35.7M
Net debt (borrowings + leases - cash) (EUR) — 13.8M 46.3M 191M -3.9M -48.4M
Cash flow detail
Operating cash flow (EUR) — 71.5M 44.8M 5.1M 123M 129M
Purchases of property, plant and equipment (EUR) — -88.6M -167M -133M -108M -78.5M
Change in receivables (cash effect) (EUR) — -131M -29.6M 48.9M 52.2M 45.4M
Change in inventories (cash effect) (EUR) — 14M -31.7M -40.4M 94M 38.9M
Change in payables (cash effect) (EUR) — 88.9M 21.4M -52.9M -46.8M 1.6M
Dividends paid (cash effect) (EUR) — 0.00 0.00 0.00 0.00 0.00
Share buybacks (cash effect) (EUR) — 0.00 -1.3M -600,000 -100,000 0.00
Interest paid (cash effect) (EUR) — — — -6.9M -16.9M -3.7M
Share-based compensation (EUR) — — — — 2.7M 1.5M
Operating cash flow before change in receivables (EUR) — 203M 74.4M -43.8M 70.7M 83.1M
Free cash flow (OCF - PPE - intangibles) (EUR) — -17.1M -123M -128M 14.9M 50M
Income detail
Research and development expense (EUR) — 17M 21.8M 29.6M 25.8M 27.3M
Total comprehensive income (EUR) — 22.6M -7.8M -187M -145M -197M
Comprehensive income to owners (EUR) — 22.6M -7.8M -187M -145M -197M
Reported Mar 14, 2023 Mar 14, 2023 Mar 14, 2023 Apr 5, 2024 Mar 27, 2026 Mar 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

News

.stg { fill: #187A8E; } Download the pdf version Bull 0 Bear 0 Routine

Press Release
Paris, 31 July 2026

Availability of 2026 Half-Year Financial Report

EUROAPI posted today its 2026 condensed Half Year Consolidated Financial Statements for the six months ended June 30, 2026. This document is available for consultation and downloading on EUROAPI’s website: 2026 Half year results | EUROAPI This report includes notably the 2026 half-year management report, the consolidated financial
statements on 30 June 2026, and the Statutory Auditors’ review report on the half-yearly financial information.

About EUROAPI EUROAPI is focused on reinventing active pharmaceutical ingredients to sustainably meet
customers’ and patients’ needs around the world. We are a leading player with approximately 200 products in our portfolio, offering a large span of technologies while also developing innovative
molecules through our Contract Development and Manufacturing Organization (CDMO) activities.

With strong R&D capabilities and five manufacturing sites located in Europe, EUROAPI provides its clients with high-quality API solutions in more than 80 countries. Our 3000+ people are
committed to building together the future of public health by advancing and securing access to
essential active ingredients, at the core of the healthcare value chain. EUROAPI is listed on
Euronext Paris: EAPI. Find out more at www.euroapi.com and follow us on LinkedIn.

Media Relations contacts: Laurence Bollack Tel.: +33 (0)6 81 86 80 19 [email protected]

Arnaud Jacques Tel. : +33 (0)6 25 64 01 11 [email protected]

Investor Relations contacts: Sophie Palliez-Capian Tel.: +33 (0)6 87 89 33 51 [email protected]

Léa Massonneau Tel: +33 (0)7 60 32 29 50 [email protected]

  • Half year financial report 2026

pdf

16217.68Ko

  • First-half 2026 results

pdf

712.68Ko

  • H1 2026 Results presentation

pdf

2607.13Ko

  • H1 2026 Results - Webcast Transcript - 30 July 2025

pdf

119.33Ko

Webcast:

Prompts

Euroapi S.A. (ticker EAPI), listed in France.

ETFs Holding Euroapi S.A.

ETF Weight in ETF Shares Market value As of
AVDE 0.00% 70,483 $ 55.612K Nov 16, 2026
AVDV 0.00% 637,017 $ 502.613K Nov 16, 2026
AVSD 0.00% 769 $ 606.75 Nov 16, 2026
AVDS 0.00% 875 $ 690.38 Nov 16, 2026